company background image
CCXI logo

ChemoCentryx NasdaqGS:CCXI Stock Report

Last Price

US$51.99

Market Cap

US$3.7b

7D

0.1%

1Y

50.4%

Updated

23 Oct, 2022

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CCXI Stock Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.

CCXI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ChemoCentryx, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ChemoCentryx
Historical stock prices
Current Share PriceUS$51.99
52 Week HighUS$52.00
52 Week LowUS$14.95
Beta1.23
11 Month Change0.41%
3 Month Change134.51%
1 Year Change50.39%
33 Year Change558.10%
5 Year Change642.71%
Change since IPO372.64%

Recent News & Updates

ChemoCentryx shareholders approve $4.7B merger with Amgen

Oct 18

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Aug 09

Recent updates

ChemoCentryx shareholders approve $4.7B merger with Amgen

Oct 18

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Aug 09

ChemoCentryx: Revisiting The Investment Case

Jun 21

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Jun 06
ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

ChemoCentryx: Good Post-Approval Performance, But Needs More Time

Mar 03

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Feb 11
ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Jan 21
Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Checking In On ChemoCentryx

Dec 15

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Oct 09
Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

Sep 29

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Aug 24

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

Aug 11
Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

ChemoCentryx: CRL Less Likely

Jul 25

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Jul 11
ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jun 15
ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress

Jun 08

ChemoCentryx: CRL Likely

May 09

ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action

May 07

Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate

May 04

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

Mar 03
When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 04
ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price

Jan 14

Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Dec 31
Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

Dec 23
Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study

Dec 21

Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Dec 13
Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

Nov 22
Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 10

Shareholder Returns

CCXIUS BiotechsUS Market
7D0.1%0.2%-2.1%
1Y50.4%12.5%19.0%

Return vs Industry: CCXI exceeded the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: CCXI exceeded the US Market which returned -19.8% over the past year.

Price Volatility

Is CCXI's price volatile compared to industry and market?
CCXI volatility
CCXI Average Weekly Movement31.3%
Biotechs Industry Average Movement10.6%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: CCXI's share price has been volatile over the past 3 months.

Volatility Over Time: CCXI's weekly volatility has increased from 18% to 31% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996178n/awww.chemocentryx.com

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis.

ChemoCentryx, Inc. Fundamentals Summary

How do ChemoCentryx's earnings and revenue compare to its market cap?
CCXI fundamental statistics
Market capUS$3.74b
Earnings (TTM)-US$133.09m
Revenue (TTM)US$37.28m

100.3x

P/S Ratio

-28.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CCXI income statement (TTM)
RevenueUS$37.28m
Cost of RevenueUS$71.86m
Gross Profit-US$34.58m
Other ExpensesUS$98.51m
Earnings-US$133.09m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.85
Gross Margin-92.76%
Net Profit Margin-357.01%
Debt/Equity Ratio10.5%

How did CCXI perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.